What Is MACE in Medical Terms? Major Adverse Cardiovascular Events

MACE stands for Major Adverse Cardiovascular Events, a composite endpoint used in clinical trials and medical research to measure whether a treatment helps prevent the worst outcomes of heart disease. The “classical” three-point MACE bundles three serious events into a single measure: nonfatal heart attack, nonfatal stroke, and death from cardiovascular causes. Researchers count whether any of these happens to a patient and use the combined tally to judge a drug or procedure. The concept sounds straightforward, but the definition is surprisingly slippery, and how a given study defines MACE can change what its results actually mean.

The Three Events That Make Up Standard MACE

When cardiologists or regulatory agencies refer to MACE without further qualification, they almost always mean the three-point version. In 2008, the U.S. Food and Drug Administration issued guidance requiring that trials evaluating the cardiovascular safety of diabetes drugs use a three-point MACE endpoint consisting of acute myocardial infarction, stroke, and cardiovascular death. The European Medicines Agency followed with similar guidance in 2012.¹ That regulatory push made three-point MACE the closest thing the field has to a gold standard.

Each component captures something different. A nonfatal myocardial infarction (heart attack) means part of the heart muscle was damaged by blocked blood flow but the patient survived. A nonfatal stroke means a blood vessel in the brain was blocked or ruptured, causing neurological damage, but the patient lived. Cardiovascular death covers fatal heart attacks, fatal strokes, sudden cardiac death, death from heart failure, and other deaths directly caused by cardiovascular disease. Together, the three components are meant to represent the most severe things that can go wrong with your heart and blood vessels.

Why the Definition Keeps Changing From Study to Study

Despite the regulatory guidance, researchers frequently customize MACE to suit their particular study. Some trials use a four-point version that adds hospitalization for unstable angina. A five-point version adds heart failure on top of that.² Other studies swap in all-cause mortality instead of cardiovascular death alone, or add coronary revascularization procedures. One Korean study defined MACE as total death, heart attack, coronary revascularization, stroke, and hospitalization for heart failure, which is essentially a five-component endpoint with revascularization replacing unstable angina.³

A systematic review of observational studies using administrative databases found enormous variation. Only about 9% of the studies matched the standard three-point definition. None matched the four-point or five-point versions. The two most common definitions in those studies were “heart attack and stroke” (used by roughly 16% of studies) and “heart attack, stroke, and all-cause death” (about 14%). More than half of the studies used a MACE definition that matched at most one other study in the entire review.¹ In other words, MACE is less a fixed term and more a loose family of related endpoints. A separate review published in the Journal of the American College of Cardiology reached the same conclusion, describing substantial heterogeneity in how individual outcomes were selected to construct the composite.⁴

This matters for you as a reader of medical news or a patient reviewing trial results. If one study reports a 20% reduction in MACE but defined MACE as heart attack plus stroke, and another study reports a 15% reduction but included heart failure hospitalizations and revascularizations as well, those numbers are not directly comparable. The broader the definition, the more events get counted, which can dilute or inflate the apparent treatment effect depending on how the drug works. Whenever you see MACE cited, the single most useful thing you can do is check which events were actually included.

How Researchers Decide Whether an Event “Counts”

Clinical trials do not simply take a doctor’s word that a patient had a heart attack or a stroke. Large trials use independent committees, sometimes called Clinical Endpoint Committees or Clinical Events Committees, to formally adjudicate each suspected event. In the SUMMIT trial, for example, a six-member committee reviewed adverse event reports. Each event was first screened by one member, then reviewed by three. If those three disagreed, the full committee discussed the case to reach consensus.⁵ The COMPASS trial used a slightly different pipeline: site investigators filed initial reports, a computer algorithm screened those reports, unconfirmed events went to a blinded adjudication committee, and uncertain cases escalated to committee chairs who could request the full patient record.⁶

The process is labor-intensive and expensive. Physician review panels spend months poring over medical records across dozens of countries and languages. More recently, researchers have begun exploring whether artificial intelligence can handle part of this work. A 2025 paper in the Journal of the American College of Cardiology described AI-based adjudication of MACE in clinical trials, noting that the conventional physician-committee approach, while the accepted standard, demands significant resources.⁷ Whether AI can match human accuracy at scale remains an active area of investigation.

The Statistical Wrinkle in Composite Endpoints

Bundling several outcomes into a single composite endpoint has a practical advantage: it gives researchers a higher event rate, which means they can run a smaller or shorter trial and still detect a treatment effect. But the bundling introduces a problem. Most trials analyze MACE using a “time-to-first-event” approach, meaning they record only when the first qualifying event happens and ignore anything after it.⁸ A patient who has a minor heart attack followed by a fatal stroke three months later contributes the same data as a patient who has just the minor heart attack. The analysis also treats all component events as equally severe, which they plainly are not. A nonfatal heart attack and cardiovascular death are not the same thing for the patient living through them.

This is one reason clinicians sometimes want to see the individual components reported alongside the composite. A drug might “reduce MACE” mainly by preventing revascularization procedures (which are serious but rarely fatal) while doing nothing for cardiovascular death. The composite MACE result would look positive, yet the benefit is concentrated in the least severe component. Responsible trial reports will break out event rates for each component separately, and that breakdown is often more informative than the headline number.

Predicting MACE Before It Happens

Emergency departments routinely use clinical scoring systems to estimate how likely a patient with chest pain is to suffer a major cardiac event in the short term. Three scores dominate: the HEART score (History, ECG, Age, Risk factors, Troponin), the TIMI score (Thrombolysis in Myocardial Infarction), and the GRACE score (Global Registry of Acute Coronary Events). In a head-to-head comparison in chest pain patients, the HEART score outperformed the other two, with a discriminative accuracy significantly higher than TIMI or GRACE.⁹ A meta-analysis using indirect comparison methods found that both TIMI and HEART outperformed GRACE for predicting MACE, with no significant difference between TIMI and HEART themselves.¹⁰

For high-acuity chest pain patients specifically, the HEART score showed an edge. A low HEART score (3 or below) had a sensitivity of 99% and a negative predictive value of 98% for ruling out a major cardiac event within 30 days, meaning it was very good at identifying who was safe to send home.¹¹ If you ever visit an emergency room with chest pain and the doctor mentions running a “HEART score,” this is what they are doing: estimating your short-term risk of MACE to decide how aggressively to investigate.

Blood Markers That Signal Elevated Risk

Beyond clinical scores, blood-based biomarkers can help predict who is heading toward a major cardiovascular event. The classic markers are cardiac troponins (proteins released when heart muscle is injured) and natriuretic peptides like BNP (which rise when the heart is under strain). Newer biomarkers under investigation include NGAL and galectin-3, both of which have shown promise for predicting MACE and heart remodeling after a heart attack, as well as certain microRNAs that correlate with the size of the damaged area.¹²

Inflammatory markers are another growing area. A study building a risk prediction model for patients undergoing coronary stent placement found that combining several inflammation-based blood indexes with clinical variables substantially improved the ability to predict MACE over the following year, outperforming any single marker used alone.¹³ The idea is that chronic low-grade inflammation destabilizes plaques in the arteries, and capturing the degree of that inflammation through a blood test can reveal risk that traditional factors like cholesterol and blood pressure miss.

MACE Risk Around Surgery

MACE is not only tracked in heart-related settings. Patients undergoing major noncardiac surgery, such as hip replacements, cancer operations, or abdominal procedures, face a real risk of perioperative cardiac events, especially if they have underlying cardiovascular risk factors. Preoperative assessment increasingly includes tools to estimate that risk.¹⁴

CT-based coronary imaging before surgery is gaining traction. A meta-analysis found that the burden of coronary artery calcium and obstructive coronary artery disease detected on CT scans were consistently associated with perioperative MACE.¹⁵ An additional wrinkle is blood sugar: one study of noncardiac surgery patients showed a J-shaped relationship between stress-related blood glucose spikes and perioperative MACE, meaning both abnormally high and abnormally low glucose responses during surgery were tied to higher cardiovascular event rates.¹⁶ For patients facing major surgery, this is a reminder that cardiovascular risk does not pause while other medical problems are being addressed.

Sex Differences in MACE Outcomes

The relationship between sex and MACE is not as simple as “men have more heart disease.” A large cohort study of survivors of coronary heart disease found that women had a roughly 30% lower overall risk of MACE and about 40% lower risk of recurrent coronary events compared with men. But the picture flips for specific components: women had a higher risk of stroke and a modestly higher risk of heart failure and all-cause mortality.¹⁷ A separate study of patients who survived acute coronary syndrome found that women had about 35% higher odds of experiencing a MACE compared with men, though there was no difference in all-cause death.¹⁸

These results look contradictory until you consider the different populations and MACE definitions involved. The first study covered a broad population of coronary heart disease survivors with long follow-up; the second focused specifically on acute coronary syndrome survivors. A meta-analysis of patients with heart attacks and nonobstructive coronary arteries found no significant long-term sex difference in MACE overall, but women had a significantly higher risk of in-hospital MACE during the initial admission.¹⁹ The takeaway is that “who fares worse” depends on the clinical context, the time horizon, and which specific events you are counting. Lumping all cardiovascular events into a single MACE label can obscure important sex-based differences in the type of complications that occur.

Inflammatory Diseases and Elevated MACE Risk

Cardiovascular risk is not confined to people with classic risk factors like high cholesterol or smoking. Chronic inflammatory diseases carry their own independent burden. A population-based study found that patients with rheumatoid arthritis who were not on disease-modifying drugs had about 39% higher adjusted risk of MACE compared with the general population. Patients with psoriatic arthritis not on such drugs had about 24% higher risk, and even patients with psoriasis alone had a modestly elevated risk.²⁰

The underlying driver appears to be systemic inflammation itself. A cohort study confirmed that both the degree of systemic inflammation and glucocorticoid use independently raised the risk of MACE in patients with inflammatory arthritis, while methotrexate and NSAIDs appeared to be protective in rheumatoid arthritis specifically.²¹ This is an area where awareness is still catching up to the evidence. Patients with autoimmune inflammatory conditions may not think of themselves as heart patients, and their rheumatologists may not routinely screen for cardiovascular risk. But the data suggest they should be thinking about it.

Treatments That Reduce MACE

Because MACE is the primary endpoint in so many cardiovascular trials, the list of therapies shown to reduce it is long. Lipid-lowering stands out. A meta-analysis of intensive lipid-lowering therapy found a 15% reduction in MACE risk compared with less aggressive treatment, along with reductions in heart attack (about 17%) and stroke (about 19%). The number needed to treat was 56, meaning for every 56 patients given intensive therapy instead of standard therapy, one MACE event was prevented.²² A Swedish cohort study of heart attack survivors found that patients who achieved larger reductions in LDL cholesterol, particularly those who achieved at least a 50% reduction using high-intensity statins, had lower rates across every individual MACE component, including cardiovascular death, recurrent heart attack, stroke, heart failure hospitalization, and revascularization.²³

Statins are the most well-established class for this purpose, but newer agents like PCSK9 inhibitors and ezetimibe have extended the principle: the further you push LDL cholesterol down, the more MACE events you prevent, with a roughly linear relationship between cholesterol reduction and risk reduction.

What MACE Means for Quality of Life and Costs

A MACE event is not just a data point in a clinical trial. For the patient who experiences one, the consequences extend well beyond the acute episode. A study tracking over 21,000 participants across the United Kingdom and the United States found significant drops in quality of life in the year a cardiovascular event occurred: stroke and heart failure admission produced some of the steepest declines, and those reductions persisted in subsequent years. Every type of cardiovascular event also drove up hospital costs substantially.²⁴ On the economic side, U.S. data showed that the average cost of a single nonfatal MACE episode was roughly $20,000, with costs climbing when the event occurred close to a prior hospitalization.²⁵

There is also a feedback loop: patients with ischemic heart disease who report lower quality of life appear to be at higher subsequent risk of MACE, suggesting that patient-reported well-being might itself serve as a prognostic signal.²⁶ In practical terms, this means that asking patients how they feel, not just measuring their biomarkers, has clinical value.

Air Pollution and Social Vulnerability

Environmental exposures are an underappreciated driver of MACE. Research presented to the European Society of Cardiology found that long-term exposure to fine particulate air pollution (PM2.5) accelerated the development of cardiovascular risk factors like high blood pressure and diabetes, and that this accelerated accumulation of risk factors accounted for roughly a third of the association between PM2.5 exposure and MACE. The effect was amplified in socially vulnerable communities: people living in the most deprived neighborhoods experienced a stronger link between pollution exposure and MACE than those in wealthier areas.²⁷ This adds a layer of complexity to cardiovascular prevention that purely clinical interventions cannot address. You can prescribe a statin, but you cannot prescribe cleaner air or a higher income.